Compare Medpace Holdings Inc (MEDP) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Unilever plc — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Unilever plc trades at $61.66 (market cap $131.63B). The key difference: Unilever plc is far larger — about 7.8× Medpace Holdings Inc's market cap, and Unilever plc pays a 3.43% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Unilever plc for 112 Days on average.
| MEDP | UL | |
|---|---|---|
Market Cap | $16.82B | $131.63B |
Volume | 223,093 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $74.59 |
52-Week Low | $393.42 | $55.05 |
Typical Hold Time | 14 Days | 112 Days |
Enterprise Value | $16.44B | $156.65B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical outlook and mixed financial performance. Revenue declined to $50.50 billion in 2025, though net income improved to $9.47 billion, with a high net margin of 18.74%. Recent earnings have consistently missed expectations, while the company is streamlining its portfolio through a planned food business merger with McCormick, facing regulatory scrutiny.
The stock presents a cautious outlook with strong profitability metrics like a 54.56% ROE offset by valuation concerns (P/E of 21.59) and earnings misses. Risks include integration challenges from the McCormick deal and competitive pressures, but its focus on beauty and personal care offers growth potential in emerging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
